Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders.

Chemistry (Weinheim an der Bergstrasse, Germany)

Marzullo P, Boiarska Z, Pérez-Peña H, Abel AC, Álvarez-Bernad B, Lucena-Agell D, Vasile F, Sironi M, Altmann KH, Prota AE, Díaz JF, Pieraccini S, Passarella D.
PMID: 34788896
Chemistry. 2022 Jan 10;28(2):e202103520. doi: 10.1002/chem.202103520. Epub 2021 Nov 29.

Maytansinol is a valuable precursor for the preparation of maytansine derivatives (known as maytansinoids). Inspired by the intriguing structure of the macrocycle and the success in targeted cancer therapy of the derivatives, we explored the maytansinol acylation reaction. As...

Cite
Marzullo P, Boiarska Z, Pérez-Peña H, et al. Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders. Chemistry. 2021;28(2):e202103520doi: 10.1002/chem.202103520.
Marzullo, P., Boiarska, Z., Pérez-Peña, H., Abel, A. C., Álvarez-Bernad, B., Lucena-Agell, D., Vasile, F., Sironi, M., Altmann, K. H., Prota, A. E., Díaz, J. F., Pieraccini, S., & Passarella, D. (2022). Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders. Chemistry (Weinheim an der Bergstrasse, Germany), 28(2), e202103520. https://doi.org/10.1002/chem.202103520
Marzullo, Paola, et al. "Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders." Chemistry (Weinheim an der Bergstrasse, Germany) vol. 28,2 (2022): e202103520. doi: https://doi.org/10.1002/chem.202103520
Marzullo P, Boiarska Z, Pérez-Peña H, Abel AC, Álvarez-Bernad B, Lucena-Agell D, Vasile F, Sironi M, Altmann KH, Prota AE, Díaz JF, Pieraccini S, Passarella D. Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders. Chemistry. 2022 Jan 10;28(2):e202103520. doi: 10.1002/chem.202103520. Epub 2021 Nov 29. PMID: 34788896.
Copy Download .nbib Format: NLM
Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates.

Cancers

Ding H, Altai M, Rinne SS, Vorobyeva A, Tolmachev V, Gräslund T, Orlova A.
PMID: 31416167
Cancers (Basel). 2019 Aug 14;11(8). doi: 10.3390/cancers11081168.

Affibody molecules are small affinity-engineered scaffold proteins which can be engineered to bind to desired targets. The therapeutic potential of using an affibody molecule targeting HER2, fused to an albumin-binding domain (ABD) and conjugated with the cytotoxic maytansine derivate...

Cite
Ding H, Altai M, Rinne SS, et al. Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates. Cancers (Basel). 2019;11(8)doi: 10.3390/cancers11081168.
Ding, H., Altai, M., Rinne, S. S., Vorobyeva, A., Tolmachev, V., Gräslund, T., & Orlova, A. (2019). Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates. Cancers, 11(8), . https://doi.org/10.3390/cancers11081168
Ding, Haozhong, et al. "Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates." Cancers vol. 11,8 (2019). doi: https://doi.org/10.3390/cancers11081168
Ding H, Altai M, Rinne SS, Vorobyeva A, Tolmachev V, Gräslund T, Orlova A. Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates. Cancers (Basel). 2019 Aug 14;11(8). doi: 10.3390/cancers11081168. PMID: 31416167; PMCID: PMC6721809.
Copy Download .nbib Format: NLM
Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders.

Chemistry (Weinheim an der Bergstrasse, Germany)

Marzullo P, Boiarska Z, Pérez-Peña H, Abel AC, Álvarez-Bernad B, Lucena-Agell D, Vasile F, Sironi M, Altmann KH, Prota AE, Díaz JF, Pieraccini S, Passarella D.
PMID: 34788896
Chemistry. 2021 Nov 17; doi: 10.1002/chem.202103520. Epub 2021 Nov 17.

Maytansinol is a valuable precursor for the preparation of maytansine derivatives (known as maytansinoids). Inspired by the intriguing structure of the macrocycle and the success in targeted cancer therapy of the derivatives, we explored the maytansinol acylation reaction. As...

Cite
Marzullo P, Boiarska Z, Pérez-Peña H, et al. Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders. Chemistry. 2021;doi: 10.1002/chem.202103520.
Marzullo, P., Boiarska, Z., Pérez-Peña, H., Abel, A. C., Álvarez-Bernad, B., Lucena-Agell, D., Vasile, F., Sironi, M., Altmann, K. H., Prota, A. E., Díaz, J. F., Pieraccini, S., & Passarella, D. (2021). Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders. Chemistry (Weinheim an der Bergstrasse, Germany), . https://doi.org/10.1002/chem.202103520
Marzullo, Paola, et al. "Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders." Chemistry (Weinheim an der Bergstrasse, Germany) vol. (2021). doi: https://doi.org/10.1002/chem.202103520
Marzullo P, Boiarska Z, Pérez-Peña H, Abel AC, Álvarez-Bernad B, Lucena-Agell D, Vasile F, Sironi M, Altmann KH, Prota AE, Díaz JF, Pieraccini S, Passarella D. Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders. Chemistry. 2021 Nov 17; doi: 10.1002/chem.202103520. Epub 2021 Nov 17. PMID: 34788896.
Copy Download .nbib Format: NLM
Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma.

Oncotarget

Cho N, Ko S, Shokeen M.
PMID: 34611478
Oncotarget. 2021 Sep 28;12(20):2039-2050. doi: 10.18632/oncotarget.28074. eCollection 2021 Sep 28.

Daratumumab (DARA) is an FDA-approved high-affinity monoclonal antibody targeting CD38 that has shown promising therapeutic efficacy in double refractory multiple myeloma (MM) patients. Despite the well-established clinical efficacy of DARA, not all heavily pretreated patients respond to single-agent DARA,...

Cite
Cho N, Ko S, Shokeen M. Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma. Oncotarget. 2021;12(20):2039-2050doi: 10.18632/oncotarget.28074.
Cho, N., Ko, S., & Shokeen, M. (2021). Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma. Oncotarget, 12(20), 2039-2050. https://doi.org/10.18632/oncotarget.28074
Cho, Nicholas, et al. "Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma." Oncotarget vol. 12,20 (2021): 2039-2050. doi: https://doi.org/10.18632/oncotarget.28074
Cho N, Ko S, Shokeen M. Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma. Oncotarget. 2021 Sep 28;12(20):2039-2050. doi: 10.18632/oncotarget.28074. eCollection 2021 Sep 28. PMID: 34611478; PMCID: PMC8487729.
Copy Download .nbib Format: NLM
Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer.

Antibodies (Basel, Switzerland)

Harel ET, Drake PM, Barfield RM, Lui I, Farr-Jones S, Van't Veer L, Gartner ZJ, Green EM, Lourenço AL, Cheng Y, Hann BC, Rabuka D, Craik CS.
PMID: 31694242
Antibodies (Basel). 2019 Nov 05;8(4). doi: 10.3390/antib8040054.

A promising molecular target for aggressive cancers is the urokinase receptor (uPAR). A fully human, recombinant antibody that binds uPAR to form a stable complex that blocks uPA-uPAR interactions (2G10) and is internalized primarily through endocytosis showed efficacy in...

Cite
Harel ET, Drake PM, Barfield RM, et al. Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer. Antibodies (Basel). 2019;8(4)doi: 10.3390/antib8040054.
Harel, E. T., Drake, P. M., Barfield, R. M., Lui, I., Farr-Jones, S., Van't Veer, L., Gartner, Z. J., Green, E. M., Lourenço, A. L., Cheng, Y., Hann, B. C., Rabuka, D., & Craik, C. S. (2019). Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer. Antibodies (Basel, Switzerland), 8(4), . https://doi.org/10.3390/antib8040054
Harel, Efrat T, et al. "Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer." Antibodies (Basel, Switzerland) vol. 8,4 (2019). doi: https://doi.org/10.3390/antib8040054
Harel ET, Drake PM, Barfield RM, Lui I, Farr-Jones S, Van't Veer L, Gartner ZJ, Green EM, Lourenço AL, Cheng Y, Hann BC, Rabuka D, Craik CS. Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer. Antibodies (Basel). 2019 Nov 05;8(4). doi: 10.3390/antib8040054. PMID: 31694242; PMCID: PMC6963874.
Copy Download .nbib Format: NLM
Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft.

Oncotarget

Hartimath SV, El-Sayed A, Makhlouf A, Bernhard W, Gonzalez C, Hill W, Parada AC, Barreto K, Geyer CR, Fonge H.
PMID: 30800216
Oncotarget. 2019 Feb 01;10(10):1031-1044. doi: 10.18632/oncotarget.26613. eCollection 2019 Feb 01.

Nimotuzumab is a humanized anti-epidermal growth factor receptor I (EGFR) monoclonal antibody. We have developed antibody drug conjugates (ADCs) with nimotuzumab conjugated to PEGylated-maytansine (PEG

Cite
Hartimath SV, El-Sayed A, Makhlouf A, et al. Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. Oncotarget. 2019;10(10):1031-1044doi: 10.18632/oncotarget.26613.
Hartimath, S. V., El-Sayed, A., Makhlouf, A., Bernhard, W., Gonzalez, C., Hill, W., Parada, A. C., Barreto, K., Geyer, C. R., & Fonge, H. (2019). Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. Oncotarget, 10(10), 1031-1044. https://doi.org/10.18632/oncotarget.26613
Hartimath, Siddesh V, et al. "Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft." Oncotarget vol. 10,10 (2019): 1031-1044. doi: https://doi.org/10.18632/oncotarget.26613
Hartimath SV, El-Sayed A, Makhlouf A, Bernhard W, Gonzalez C, Hill W, Parada AC, Barreto K, Geyer CR, Fonge H. Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. Oncotarget. 2019 Feb 01;10(10):1031-1044. doi: 10.18632/oncotarget.26613. eCollection 2019 Feb 01. PMID: 30800216; PMCID: PMC6383682.
Copy Download .nbib Format: NLM
Assessment of General Public's Knowledge and Opinions towards Antibiotic Use and Bacterial Resistance: A Cross-Sectional Study in an Urban Setting, Rufisque, Senegal.

Pharmacy (Basel, Switzerland)

Bassoum O, Sougou NM, Diongue M, Lèye MMM, Mbodji M, Fall D, Seck I, Faye A, Tal-Dia A.
PMID: 30241307
Pharmacy (Basel). 2018 Sep 20;6(4). doi: 10.3390/pharmacy6040103.

No abstract available.

Cite
Bassoum O, Sougou NM, Diongue M, et al. Assessment of General Public's Knowledge and Opinions towards Antibiotic Use and Bacterial Resistance: A Cross-Sectional Study in an Urban Setting, Rufisque, Senegal. Pharmacy (Basel). 2018;6(4)doi: 10.3390/pharmacy6040103.
Bassoum, O., Sougou, N. M., Diongue, M., Lèye, M. M. M., Mbodji, M., Fall, D., Seck, I., Faye, A., & Tal-Dia, A. (2018). Assessment of General Public's Knowledge and Opinions towards Antibiotic Use and Bacterial Resistance: A Cross-Sectional Study in an Urban Setting, Rufisque, Senegal. Pharmacy (Basel, Switzerland), 6(4), . https://doi.org/10.3390/pharmacy6040103
Bassoum, Oumar, et al. "Assessment of General Public's Knowledge and Opinions towards Antibiotic Use and Bacterial Resistance: A Cross-Sectional Study in an Urban Setting, Rufisque, Senegal." Pharmacy (Basel, Switzerland) vol. 6,4 (2018). doi: https://doi.org/10.3390/pharmacy6040103
Bassoum O, Sougou NM, Diongue M, Lèye MMM, Mbodji M, Fall D, Seck I, Faye A, Tal-Dia A. Assessment of General Public's Knowledge and Opinions towards Antibiotic Use and Bacterial Resistance: A Cross-Sectional Study in an Urban Setting, Rufisque, Senegal. Pharmacy (Basel). 2018 Sep 20;6(4). doi: 10.3390/pharmacy6040103. PMID: 30241307; PMCID: PMC6306938.
Copy Download .nbib Format: NLM
Trastuzumab Emtansine (T-DM1): Hitching a Ride on a Therapeutic Antibody.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Burris HA.
PMID: 24451727
Am Soc Clin Oncol Educ Book. 2012;159-61. doi: 10.14694/EdBook_AM.2012.32.109.

The treatment of cancers with chemotherapy is frequently limited by side effects. The effectiveness may be improved by the use of monoclonal antibodies to deliver cytotoxic agents to cancer cells while limiting exposure to normal tissues. The use of...

Cite
Burris HA. Trastuzumab Emtansine (T-DM1): Hitching a Ride on a Therapeutic Antibody. Am Soc Clin Oncol Educ Book. 2012;159-61doi: 10.14694/EdBook_AM.2012.32.109.
Burris, H. A. (2012). Trastuzumab Emtansine (T-DM1): Hitching a Ride on a Therapeutic Antibody. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 159-61. https://doi.org/10.14694/EdBook_AM.2012.32.109
Burris, Howard A. "Trastuzumab Emtansine (T-DM1): Hitching a Ride on a Therapeutic Antibody." American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting vol. (2012): 159-61. doi: https://doi.org/10.14694/EdBook_AM.2012.32.109
Burris HA. Trastuzumab Emtansine (T-DM1): Hitching a Ride on a Therapeutic Antibody. Am Soc Clin Oncol Educ Book. 2012;159-61. doi: 10.14694/EdBook_AM.2012.32.109. PMID: 24451727.
Copy Download .nbib Format: NLM
Trastuzumab-emtansine induced pleural and pericardial effusions.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Lombardi J, Lory P, Martin N, Mayeur D, Combret S, Grandvuillemin A, Boulay C, Schmitt A.
PMID: 34000917
J Oncol Pharm Pract. 2021 May 18;10781552211015772. doi: 10.1177/10781552211015772. Epub 2021 May 18.

INTRODUCTION: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate which combine trastuzumab (T), a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), and a cytotoxic molecule derived from maytansine (DM1).CASE REPORT: We report the first case of T-DM1-associated...

Cite
Lombardi J, Lory P, Martin N, et al. Trastuzumab-emtansine induced pleural and pericardial effusions. J Oncol Pharm Pract. 2021;10781552211015772doi: 10.1177/10781552211015772.
Lombardi, J., Lory, P., Martin, N., Mayeur, D., Combret, S., Grandvuillemin, A., Boulay, C., & Schmitt, A. (2021). Trastuzumab-emtansine induced pleural and pericardial effusions. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 10781552211015772. https://doi.org/10.1177/10781552211015772
Lombardi, Jeffrey, et al. "Trastuzumab-emtansine induced pleural and pericardial effusions." Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners vol. (2021): 10781552211015772. doi: https://doi.org/10.1177/10781552211015772
Lombardi J, Lory P, Martin N, Mayeur D, Combret S, Grandvuillemin A, Boulay C, Schmitt A. Trastuzumab-emtansine induced pleural and pericardial effusions. J Oncol Pharm Pract. 2021 May 18;10781552211015772. doi: 10.1177/10781552211015772. Epub 2021 May 18. PMID: 34000917.
Copy Download .nbib Format: NLM
Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer.

International journal of cancer

Tang SC, Capra CL, Ajebo GH, Meza-Junco J, Mairs S, Craft BS, Zhu X, Maihle N, Hillegass WB.
PMID: 33844843
Int J Cancer. 2021 Apr 12; doi: 10.1002/ijc.33597. Epub 2021 Apr 12.

The mechanism by which trastuzumab-emtansine (T-DM1) causes systemic toxicities apart from trastuzumab alone is currently unknown. We hypothesized that the systemic toxicities from T-DM1 may have been caused by the free and active maytansine released from the lysed HER2+...

Cite
Tang SC, Capra CL, Ajebo GH, et al. Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer. Int J Cancer. 2021;doi: 10.1002/ijc.33597.
Tang, S. C., Capra, C. L., Ajebo, G. H., Meza-Junco, J., Mairs, S., Craft, B. S., Zhu, X., Maihle, N., & Hillegass, W. B. (2021). Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer. International journal of cancer, . https://doi.org/10.1002/ijc.33597
Tang, Shou-Ching, et al. "Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer." International journal of cancer vol. (2021). doi: https://doi.org/10.1002/ijc.33597
Tang SC, Capra CL, Ajebo GH, Meza-Junco J, Mairs S, Craft BS, Zhu X, Maihle N, Hillegass WB. Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer. Int J Cancer. 2021 Apr 12; doi: 10.1002/ijc.33597. Epub 2021 Apr 12. PMID: 33844843; PMCID: PMC8360077.
Copy Download .nbib Format: NLM
Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine.

Cancer management and research

Recondo G, de la Vega M, Galanternik F, Díaz-Cantón E, Leone BA, Leone JP.
PMID: 27274311
Cancer Manag Res. 2016 May 19;8:57-65. doi: 10.2147/CMAR.S104447. eCollection 2016.

The human epidermal growth factor receptor 2 (HER2) is overexpressed in 20% of breast carcinomas. Prior to the development of targeted therapies, HER2-positive breast cancer was associated with more aggressive disease and poor prognosis. Trastuzumab emtansine (T-DM1) is an...

Cite
Recondo G, de la Vega M, Galanternik F, et al. Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine. Cancer Manag Res. 2016;8:57-65doi: 10.2147/CMAR.S104447.
Recondo, G., de la Vega, M., Galanternik, F., Díaz-Cantón, E., Leone, B. A., & Leone, J. P. (2016). Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine. Cancer management and research, 857-65. https://doi.org/10.2147/CMAR.S104447
Recondo, Gonzalo, et al. "Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine." Cancer management and research vol. 8 (2016): 57-65. doi: https://doi.org/10.2147/CMAR.S104447
Recondo G, de la Vega M, Galanternik F, Díaz-Cantón E, Leone BA, Leone JP. Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine. Cancer Manag Res. 2016 May 19;8:57-65. doi: 10.2147/CMAR.S104447. eCollection 2016. PMID: 27274311; PMCID: PMC4876844.
Copy Download .nbib Format: NLM
Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth.

Molecular therapy. Nucleic acids

Yoon S, Huang KW, Reebye V, Spalding D, Przytycka TM, Wang Y, Swiderski P, Li L, Armstrong B, Reccia I, Zacharoulis D, Dimas K, Kusano T, Shively J, Habib N, Rossi JJ.
PMID: 28325302
Mol Ther Nucleic Acids. 2017 Mar 17;6:80-88. doi: 10.1016/j.omtn.2016.11.008. Epub 2016 Dec 10.

Aptamer-drug conjugates (ApDCs) have the potential to improve the therapeutic index of traditional chemotherapeutic agents due to their ability to deliver cytotoxic drugs specifically to cancer cells while sparing normal cells. This study reports on the conjugation of cytotoxic...

Cite
Yoon S, Huang KW, Reebye V, et al. Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth. Mol Ther Nucleic Acids. 2016;6:80-88doi: 10.1016/j.omtn.2016.11.008.
Yoon, S., Huang, K. W., Reebye, V., Spalding, D., Przytycka, T. M., Wang, Y., Swiderski, P., Li, L., Armstrong, B., Reccia, I., Zacharoulis, D., Dimas, K., Kusano, T., Shively, J., Habib, N., & Rossi, J. J. (2017). Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth. Molecular therapy. Nucleic acids, 680-88. https://doi.org/10.1016/j.omtn.2016.11.008
Yoon, Sorah, et al. "Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth." Molecular therapy. Nucleic acids vol. 6 (2017): 80-88. doi: https://doi.org/10.1016/j.omtn.2016.11.008
Yoon S, Huang KW, Reebye V, Spalding D, Przytycka TM, Wang Y, Swiderski P, Li L, Armstrong B, Reccia I, Zacharoulis D, Dimas K, Kusano T, Shively J, Habib N, Rossi JJ. Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth. Mol Ther Nucleic Acids. 2017 Mar 17;6:80-88. doi: 10.1016/j.omtn.2016.11.008. Epub 2016 Dec 10. PMID: 28325302; PMCID: PMC5363417.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries